Innovent Biologics H1 Product Revenue Exceeds RMB 8.2 Billion, Up Over 55%
Innovent Biologics reported product revenue of over RMB 8.2 billion in the first half of 2026, a year-on-year increase of more than 55%, with second-quarter revenue exceeding RMB 4.3 billion. The company is advancing three core innovative assets into global Phase III clinical trials and has over 20 collaboration projects with multinational pharmaceutical firms including Pfizer, Eli Lilly, Takeda, and Roche.
In the first half of 2026, Innovent Biologics generated product revenue of over RMB 8.2 billion, representing a year-on-year increase of more than 55%. Product revenue for the second quarter alone exceeded RMB 4.3 billion, up approximately 60% from the same period last year.
The company is advancing three core innovative assets into global Phase III clinical studies, while continuing to expand its next-generation innovation pipeline in oncology, cardiovascular and metabolic diseases, autoimmune disorders, and ophthalmology. Innovent currently has over 20 collaboration programs with multinational pharmaceutical companies such as Pfizer, Eli Lilly, Takeda, and Roche, including five co-development and co-commercialization pipelines.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Biotechnology, with intensity 65/100 and 80% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.